Regeneron (REGN -8.5%) dives after privately-owned Opthotech reports positive Phase 2b results...

|About: Regeneron Pharmaceuticals, ... (REGN)|By:, SA News Editor

Regeneron (REGN -8.5%) dives after privately-owned Opthotech reports positive Phase 2b results for its Fovista drug. Fovista, working in tandem with Roche's (RHHBY.PK) Lucentis, treats a form of macular degeneration, and stands to compete with Regeneron's Eylea. Lucentis. Jefferies is defending Regeneron, arguing Fovista could just as well work in tandem with Eylea.